Commission Decision of 23 February 2005 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2004 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2005) 293) (Only the Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Portuguese, Slovenian and Spanish texts are authentic) (Text with EEA relevance) (2005/171/EC)
Grade B
mapped from publisher markup. A grade says how a document's structure was obtained, not how reliable the law is.
Address https://gelex.eu/eli/EU/decision/2005/171@2005-02-23/en
THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,
Having regard to Regulation (EC) No 2037/2000 of the European Parliament and of the Council of 29 June 2000 on substances that deplete the ozone layer, and in particular Article 3(1) thereof,
Whereas:
(1) The Community has already phased out the production and consumption of chlorofluorocarbons, other fully halogenated chlorofluorocarbons, halons, carbon tetrachloride,1,1,1-trichloroethane, hydrobromofluorocarbon and bromo-chloromethane.
(2) Each year the Commission has to determine essential uses for these controlled substances, the quantities that may be used and the companies that may use them.
(3) Decision IV/25 of the Parties to the Montreal Protocol on substances that deplete the ozone layer, hereinafter the Montreal Protocol, sets out the criteria used by the Commission for determining any essential uses and authorises the production and consumption necessary to satisfy essential uses of controlled substances in each Party.
(4) Decision XV/8 of the Parties to the Montreal Protocol authorises the production and consumption necessary to satisfy essential uses of controlled substances listed in Annexes A, B and C (Group II and III substances) of the Montreal Protocol for laboratory and analytical uses as listed in Annex IV to the report of the seventh Meeting of the Parties, subject to the conditions set out in Annex II to the report of the sixth Meeting of the Parties, Decision VII/11 and Decision XI/15 of the Parties to the Montreal Protocol.
(5) Pursuant to paragraph 3 of Decision XII/2 of the 12th Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Luxembourg, Norway, Portugal, the Netherlands, Sweden and the United Kingdom have notified the United Nations Environment Programme that chlorofluorocarbons (CFCs) are no longer essential for the manufacture of specific short-acting beta agonist CFC-MDIs. Article 4(4)(i)(b) of Regulation (EC) No 2037/2000 prevents CFCs from being used and placed on the market unless they are considered essential under the conditions described in Article 3(1) of that Regulation. These non-essentiality determinations have reduced the demand for CFCs in the Community. In addition, Article 4(6) prevents CFC-MDI products being imported and placed on the market unless the CFCs in these products are considered essential under the conditions described in Article 3(1).
(6) The Commission published a notice on 11 July 2003 to those companies in the Community (15) that request consideration by the Commission for the use of controlled substances for essential uses in the Community in 2004 and a further notification to companies in the 10 new Member States on 11 May 2004, and has received declarations on intended essential uses of controlled substances in 2004.
(7) Commission Decision 2004/209/EC of 28 January 2004 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2004 pursuant to Regulation (EC) No 2037/2000 of the European Parliament and of the Council should be amended in order to take account of the inclusion of specific quantities of ozone depleting substances required for essential uses in the 10 new Member States from 1 May 2004.
(8) In the interests of legal clarity and transparency Decision 2004/209/EC should therefore be replaced.
(9) The measures provided for in this Decision are in accordance with the opinion of the Management Committee established by Article 18(1) of Regulation (EC) No 2037/2000,
HAS ADOPTED THIS DECISION:
Article 1
1. The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) subject to Regulation (EC) No 2037/2000 which may be used for essential medical uses in the Community in 2004 shall be 1428533,000 ODP (ozone depletion potential) kilograms.
2. The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) and Group II (other fully halogenated chlorofluorocarbons) subject to Regulation (EC) No 2037/2000 which may be used for essential laboratory uses in the Community in 2004 shall be 73336,765 ODP kilograms.
3. The quantity of controlled substances of Group III (halons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory use in the Community in 2004 shall be 19268,700 ODP kilograms.
4. The quantity of controlled substances of Group IV (carbon tetrachloride) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2004 shall be 141834,000 ODP kilograms.
5. The quantity of controlled substances of Group V (1,1,1-trichloroethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the European Union in 2004 shall be 529,300 ODP kilograms.
6. The quantity of controlled substances of Group VII (hydrobromofluorocarbons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2004 shall be 3,070 ODP kilograms.
7. The quantity of controlled substances of group IX (bromochloromethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2004 shall be 13,248 ODP kilograms.
Article 2
The chlorofluorocarbon metered-dose inhalers (CFC-MDIs) listed in Annex I shall not be placed on markets that have determined CFCs for these products to be non-essential.
Article 3
During the period 1 January to 31 December 2004 the following rules shall apply:
1. The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II.
2. The allocation of essential laboratory use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III.
3. The allocation of essential laboratory use quotas for halons shall be to the companies indicated in Annex IV.
4. The allocation of essential laboratory use quotas for carbon tetrachloride shall be to the companies indicated in Annex V.
5. The allocation of essential laboratory use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI.
6. The allocation of essential laboratory use quotas for hydrobromofluorocarbons shall be to the companies indicated in Annex VII.
7. The allocation of essential laboratory use quotas for bromochloromethane shall be to the companies indicated in Annex VIII.
8. The essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, other fully halogenated chlorofluorocarbons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbons and bromochloromethane shall be as set out in Annex IX.
Article 4
Decision 2004/209/EC is repealed. References to the repealed Decision shall be construed as references to this Decision.
Article 5
This Decision is addressed to the following undertakings:
3M Health Care Ltd 3M House Morley Street Loughborough Leicestershire LE11 1EP United Kingdom
Aventis London Road, Holmes Chapel Cheshire CW4 8BE United Kingdom
Bespak PLC North Lynn Industrial Estate King's Lynn Norfolk PE30 2JJ United Kingdom
Boehringer Ingelheim GmbH Binger Strasse 173 D-55216 Ingelheim am Rhein
Chiesi Farmaceutici SpA Via Palermo 26/A I-43100 Parma
GlaxoSmithKline Speke Boulevard Speke Liverpool L24 9JD United Kingdom
IG Sprühtechnik GmbH Im Hemmet 1 D-79664 Wehr
Inyx Pharmaceuticals Ltd Astmoor Industrial Estate 9 Arkwright Road Runcorn Cheshire WA7 1NU United Kingdom
IVAX Ltd Unit 301 Industrial Park Waterford Ireland
Jaba Farmaceutica SA Rua da Tapada Grande, 2 P-2710-089, Abrunheira Sintra
Laboratorio Aldo Union SA Baronesa de Maldá 73 Espluges de Llobregat E-08950 Barcelona
Otsuka Pharmaceuticals (E) Provenca, 388 E-08025 Barcelona
SICOR SpA Via Terrazzano 77 I-20017 RHO Milano
Schering-Plough Labo NV Industriepark 30 B-2220 Heist Op Den Berg
Valvole Aerosol Research Italiana (VARI) Spa — LINDAL Group Italia Via del Pino, 10 Olginate (LC) I-23854 Italia
Valeas SpA Pharmaceuticals Via Vallisneri, 10 I-20133 Milano
Valois SA 50 avenue de l’Europe F-78160 Marly-Le-Roi
Acros Organics bvba Janssen Pharmaceuticalaan 3a B-2440 Geel
Airbus France 316, route de Bayonne F-31300 Toulouse
Agfa-Gevaert NV Septestraat 27 B-2640 Mortsel
Bie & Berntsen Sandbækvej 7 DK-2610 Rødovre
Biosolove BV Waalreseweg 17 5554 HA Valkenswaard The Netherlands
Butterworth Laboratories Ltd 54 Waldegrave Road, Teddington Middlesex TW11 8NY United Kingdom
Carl Roth GmbH Schoemperlenstr. 1—5 D-76185 Karlsruhe
Elcom Group Okružní 988 CZ-735 14 Orlová — Lutyně
Environnement SA 111, Bld Robespierre BP 4513 F-78304 Poissy
Fisher Scientific Bishop Meadow Road Loughborough LE11 5RG United Kingdom
Health Protection Inspectorate-Laboratories Paldiski mnt 81 EE-10617 Tallinn
Honeywell Specialty Chemicals Wunstorfer Straße 40 Postfach 100262 D-30918 Seelze
Institut scientifique de service public (ISSeP) Rue du Chéra 200 B-4000 Liège
Institut E. Malvoz (B) Quai du Barbou, 4 B-4000 Liège
Ineos Fluor Ltd PO Box 13, The Heath Runcorn Cheshire WA7 4QF United Kingdom
Katholieke Universiteit Leuven Krakenstraat 3 B-3000 Leuven
Laboratoires sérobiologiques 3, rue de Seichamps F-54425 Pulnoy
LGC Promochem GmbH Mercatorstr. 51 D-46485 Wesel
Mallinckrodt Baker BV Teugseweg 20 7418 AM Deventer The Netherlands
Merck KgaA Frankfurter Strasse 250 D-64271 Darmstadt
Mikro+Polo d.o.o. Lackova 78 SLO-2000 Maribor
Panreac Química SA Riera de Sant Cugat 1 E-08110 Montcada I Reixac (Barcelona)
Rohs Chemie GmbH Berliner Str. 54 D-53819 Neunkirchen-Seelsheid
Sanolabor d.d. Leskoškova 4 SLO-Ljubljana
SDS Solvants, Documentation, Synthèses SA Z.I. de Valdonne, BP 4 F-13124 Peypin
Sigma Aldrich Chemie GmbH Riedstrasse 2 D-89555 Steinheim
Sigma Aldrich Chimie SARL 80 rue de Luzais L'Isle-d'Abeau Chesnes F-38297 St-Quentin-Fallavier
Sigma Aldrich Company Ltd The Old Brickyard New Road Gillingham SP8 4XT United Kingdom
Sigma Aldrich Laborchemikalien Wunstorfer Straße 40, Postfach 100262 D-30918 Seelze
VWR I.S.A.S. 201, rue Carnot F-94126 Fontenay-sous-bois
University Of Technology Vienna Institut of Industrial Electronics and Material Science Gusshausstrasse 27-29 A-1040 Wien
YA-Kemia Oy — Sigma-Aldrich Finland Teerisuonkuja 4 FI-00700 Helsinki
Done at Brussels, 23 February 2005. For the Commission Stavros Dimas Member of the Commission
ANNEX
ANNEX I
Pursuant to paragraph 3 of Decision XII/2 of the 12th Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following Parties have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as essential under the Protocol when combined with following products: Source: www.unep.org/ozone/dec12-2-3.pdf Product Country Salbutamol Terbutaline Fenoterol Orciprenaline Reproterol Carbuterol Hexoprenaline Pirbuterol Clenbuterol Bitolterol Procaterol Beclomethasone Dexamethasone Fluinisolide Fluiticasone Budesonide Triamcinolone Ipratropium bromide Oxitropium Bromide Austria X X X X X X X X X X X Belgium X X X X X X X X X X X Czech Republic X X X X X X X X X X X Denmark X X X X X X X X X X X Finland X France X Germany X X X X X X X X X X X X X X X X X X X Greece X X X X X X X X X X X Ireland X Luxembourg X Portugal X X X X X X X X X X X The Netherlands X X X X X X X X X X X Norway X X X X X X X X X X X Sweden X UK X
ANNEX II ESSENTIAL MEDICAL USES
Quota of controlled substances of Group I that may be used in the production of metered-dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:
3M (UK)
Aventis (UK)
Bespak (UK)
Boehringer Ingelheim (DE)
Chiesi (IT)
Glaxo Smith Kline (UK)
IG Sprühtechnik (DE)
Inyx Pharmaceuticals (UK)
IVAX (IE)
Jaba Farmaceutica (PT)
Lab. Aldo-Union (ES)
Otsuka Pharmaceuticals (ES)
Sicor (IT)
Schering-Plough (BE)
V.A.R.I. (IT)
Valeas (IT)
Valois (FR)
ANNEX III ESSENTIAL LABORATORY USES
Quota of controlled substances of Group I and II that may be used for laboratory and analytical uses, are allocated to:
Agfa-Gevaert (BE)
Bie & Berntsen (DK)
Butterworth Laboratories (UK)
Biosolve (NL)
Carl Roth (DE)
Elcom Group (CZ)
Environnement SA (FR)
Honeywell Specialty Chemicals (DE)
Ineos Fluor (UK)
Katholieke Universiteit Leuven (BE)
LGC Promochem (DE)
Mallinckrodt Baker (NL)
Merck KGaA (DE)
Mikro + Polo (SI)
Panreac Química (ES)
SDS Solvants (FR)
Sanolabor (SI)
Sigma Aldrich Chemie (DE)
Sigma Aldrich Chimie (FR)
Sigma Aldrich Company (UK)
University Of Technology Vienna (AT)
Ya Kemia Oy — Sigma Aldrich (FI)
ANNEX IV ESSENTIAL LABORATORY USES
Quota of controlled substances of Group III that may be used for laboratory and analytical uses are allocated to:
Airbus France (FR)
Butterworth Laboratories (UK)
Ineos Fluor (UK)
Sigma Aldrich Chimie (FR)
Sigma Aldrich Company (UK)
ANNEX V ESSENTIAL LABORATORY USES
Quota of controlled substances of Group IV that may be used for laboratory and analytical uses, are allocated to:
Acros Organics (BE)
Agfa-Gevaert (BE)
Bie & Berntsen (DK)
Biosolve (NL)
Butterworth Laboratories (UK)
Fisher Scientific (UK)
Health Protection Inspectorate-Laboratories (EE)
Institut E. Malvoz (BE)
Institut Scientifique de Service Public (ISSeP) (BE)
Katholieke Universiteit Leuven (BE)
Laboratoires Sérologiques (FR)
Mallinckrodt Baker (NL)
Merck KGaA (DE)
Mikro + Polo (SI)
Panreac Química (ES)
Rohs Chemie (DE)
SDS Solvants (FR)
Sanolabor d.d. (SI)
Sigma Aldrich Chemie (DE)
Sigma Aldrich Chimie (FR)
Sigma Aldrich Company (UK)
Sigma Aldrich Laborchemikalien (DE)
VWR I.S.A.S. (FR)
YA-Kemia Oy (FI)
ANNEX VI ESSENTIAL LABORATORY USES
Quota of controlled substances of Group V that may be used for laboratory and analytical uses are allocated to:
Acros Organics (BE)
Agfa-Gevaert (BE)
Bie & Berntsen (DK)
Katholieke Universiteit Leuven (BE)
Mallinckrodt Baker (NL)
Mikro + Polo (SI)
Panreac Química (ES)
Sanolabor d.d. (SI)
Sigma Aldrich Chemie (DE)
Sigma Aldrich Chimie (FR)
Sigma Aldrich Company (UK)
ANNEX VII ESSENTIAL LABORATORY USES
Quota of controlled substances of Group VII that may be used for laboratory and analytical uses are allocated to:
Acros Organics (BE)
Ineos Fluor (UK)
Sigma Aldrich Chimie (FR)
Sigma Aldrich Company (UK)
ANNEX VIII ESSENTIAL LABORATORY USES
Quota of controlled substances of Group IX that may be used for laboratory and analytical uses are allocated to:
Ineos Fluor (UK)
Sigma Aldrich Chemie (DE)
Sigma Aldrich Chimie (FR)
ANNEX IX
(This Annex is not published because it contains confidential commercial information.)